Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose declining demand for viral-based editing. Following a January 9, 2025 press release announcing research halting and 27% workforce reduction, NTLA's stock price dropped from $12.02 to $10.20.
April 03, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit alleges securities fraud, company discontinues NTLA-3001 research and reduces workforce, potentially impacting investor confidence
Lawsuit and strategic restructuring suggest significant operational challenges, likely to negatively impact stock price in short term
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100